MAPT and Alzheimer disease: Regarding MMSE score, [Aβ1–42]CSF, and (p-Tau/Tau)CSF, it is tempting to speculate that AD patients with high or low [NA]plasma represent an early or late stage of AD, setting [NA]plasma as a potential marker of disease evolution.